- Home
- INZY vs SPKL Comparison
INZY vs SPKL Comparison
Compare INZY & SPKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- SPKL
- Stock Information
- Founded
- INZY 2015
- SPKL 2021
- Country
- INZY United States
- SPKL United States
- Employees
- INZY N/A
- SPKL N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- SPKL
- Sector
- INZY Health Care
- SPKL
- Exchange
- INZY Nasdaq
- SPKL Nasdaq
- Market Cap
- INZY 188.2M
- SPKL 174.6M
- IPO Year
- INZY 2020
- SPKL 2023
- Fundamental
- Price
- INZY $1.34
- SPKL $10.68
- Analyst Decision
- INZY Strong Buy
- SPKL
- Analyst Count
- INZY 8
- SPKL 0
- Target Price
- INZY $17.75
- SPKL N/A
- AVG Volume (30 Days)
- INZY 770.8K
- SPKL 31.3K
- Earning Date
- INZY 03-11-2025
- SPKL 01-01-0001
- Dividend Yield
- INZY N/A
- SPKL N/A
- EPS Growth
- INZY N/A
- SPKL N/A
- EPS
- INZY N/A
- SPKL 0.19
- Revenue
- INZY N/A
- SPKL N/A
- Revenue This Year
- INZY N/A
- SPKL N/A
- Revenue Next Year
- INZY N/A
- SPKL N/A
- P/E Ratio
- INZY N/A
- SPKL $57.56
- Revenue Growth
- INZY N/A
- SPKL N/A
- 52 Week Low
- INZY $1.32
- SPKL $10.18
- 52 Week High
- INZY $7.80
- SPKL $11.95
- Technical
- Relative Strength Index (RSI)
- INZY 20.16
- SPKL 61.48
- Support Level
- INZY $1.32
- SPKL $10.63
- Resistance Level
- INZY $1.44
- SPKL $10.68
- Average True Range (ATR)
- INZY 0.25
- SPKL 0.02
- MACD
- INZY -0.12
- SPKL 0.00
- Stochastic Oscillator
- INZY 1.61
- SPKL 85.71
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
About SPKL Spark I Acquisition Corp.
Spark I Acquisition Corp is a Blank check company.